PRJNA479722
Iguratimod Dampens B cell Terminal Differentiation  by Inhibiting Egr-1 expression
Iguratimod is a small molecule drug to inhibit B cell terminal differentiation and to treat rheumatoid arthritis (RA) in Asia, but its work mechanism remains highly controversial. This study is aimed to explore the potential molecular mechanism of iguratimod in dampening human ASC differentiation and its relevance in clinical situation.